Cell-mediated immune responses predict clinical cytomegalovirus (CMV) events but have not been adopted into routine practice due to lack of interventional studies. Our objective was to demonstrate the safety and feasibility of early discontinuation of antivirals based on the real-time measurement of CMV-specific cell-mediated immunity (CMI) in patients with CMV viremia. Transplant patients were enrolled at the onset of CMV viremia requiring antiviral therapy. CD8 T cell responses were determined using the Quantiferon-CMV assay, and results were used to guide subsequent management. A total of 27 patients (median viral load at onset 10 900 International Units/mL) were treated until viral load negative. At end of treatment, 14/27 (51.9%) had a positive CMV-CMI response and had antivirals discontinued. The remaining 13/27 (48.1%) patients had a negative CMV-CMI response and received 2 months of secondary antiviral prophylaxis. In those with a positive CMI and early discontinuation of antivirals, only a single patient experienced a low-level asymptomatic recurrence. In contrast, recurrence was observed in 69.2% of CMI-negative patients despite more prolonged antivirals (p = 0.001). In conclusion, this is the first study to demonstrate the feasibility and safety of real-time CMV-specific CMI assessment to guide changes to the management of CMV infection.
Introduction
Cytomegalovirus (CMV) is the most common opportunistic viral infection after organ transplantation. CMV disease can be prevented using prophylaxis or pre-emptive therapy for CMV viremia. Both strategies are successful, but significant rates of viremia and symptomatic CMV disease still occur. Therapy for CMV viremia generally consists of treatment doses of (val)ganciclovir until viral load becomes negative. However, rates of viremia recurrence are approximately 30% after discontinuation of treatment (1) . Recurrence rates may depend on type of transplant, degree of immunosuppression, and the pretransplant donor/recipient serostatus of the patient. Therefore, some experts use secondary antiviral prophylaxis to prevent recurrence although the benefit of this approach, and in which specific patients it should be utilized, remain unknown (1, 2) .
It is well known that the host response to CMV infection is largely mediated by CD4+ and CD8+ T cell immune responses and these factors also play a role in both the initial development of viremia/disease as well as recurrent episodes (3) . Cell-mediated immunity (CMI) to CMV can be measured using a variety of methods including enzyme-linked immunosorbent assay (ELISA), ELISpot assays, as well as cytokine flow cytometry. These assays have primarily been used to measure IFN-c production from peripheral blood mononuclear cells in response to stimulation with CMV antigens. The ELISA method has been developed into a commercial assay (QuantiFERON CMV, Qiagen Inc.) that detects interferon-c (IFN-c) in response to primarily CD8+ T cell stimulation by a CMV peptide pool encompassing approximately 23 unique immunodominant viral peptides from viral pp65, IE1, IE2, and gB. Several prospective observational studies using either commercially available assays or in-house assays have clearly demonstrated the potential for measuring CD8 T cell responses (and possibly CD4 T cell responses) to predict clinically relevant events related to CMV reactivation (4, 5) . These events may include either the risk of initial viral reactivation (for example, after discontinuation of prophylaxis) or recurrence of viremia after initial therapy. Also, a positive CMI has been associated with spontaneous clearance of low level viremia (i.e. without treatment) (4-6). However, despite several years of supportive data, and the potential to allow personalized tailoring of CMV prophylaxis/treatment, CMI assays have not been adopted into routine clinical practice. In the most recent CMV international guidelines, a lack of prospective interventional studies was cited as one of the main limitations to routine clinical adoption (7) . Such interventional studies can be defined as clinical trials where a decision regarding CMV management is made in real time based on the result of a measurement of CMI. Therefore, we performed a proof-of-concept interventional study, where CMV-specific CMI measurement was performed in real time and used to guide clinical decision making with respect to antiviral therapy.
The objective of this study was to demonstrate the safety and feasibility of early discontinuation of antivirals based on the real-time measurement of CMV-specific CMI in patients with CMV viremia or disease.
Methods

Patient population
Organ transplant patients were enrolled at the onset of treatment for a first documented episode of CMV viremia. Viremia levels prior to antiviral treatment were required to be at least 1000 International Units [IU]/mL (Roche Assay with lower limit of quantitation [LLoQ] 137 IU/mL). Patients with a previous documented history of CMV viremia or disease after undergoing transplant were excluded. In addition, patients in whom the onset of viremia occurred while on (val)ganciclovir (i.e. breakthrough viremia) were excluded. Valganciclovir was given as 900 mg twice daily for treatment and ganciclovir was administered as 5 mg/kg twice daily intravenously. All doses were adjusted for creatinine clearance. Patients were treated as per standard clinical care with the above doses of (val)ganciclovir until viral load was undetectable at one time point or was <137 IU/mL on two occasions 1 week apart. This was classified as the end of treatment. Upon reaching the end of treatment, blood for CMV-specific CMI was collected using the Quantiferon-CMV assay and tested in real time (see below).
Study design
The Quantiferon-CMV assay was performed as per manufacturer's instructions (see below) and results were available within 72 h of collection. Patients remained on treatment doses of (val)ganciclovir until assay results were available. The result of the CMV-CMI assay was then used to guide further therapy as follows: patients with a positive assay (≥0.2 IU/mL IFN-c) had antivirals discontinued; patients with a negative CMI were assigned to receive 2 months of secondary antiviral prophylaxis. All patients were monitored by serial viral load testing every 2 weeks until 3 months after completion of antivirals. The primary endpoint was CMV recurrence at 6 months, defined as CMV viremia ≥500 IU/mL and re-initiation of antiviral treatment (center-specific threshold for initiation of antiviral therapy).
The trial was registered at www.clinicaltrials.gov, registration # NCT02370758. The study was approved by the institutional research ethics board and all patients provided informed consent.
Laboratory testing CMV Quantiferon assay: For assessment of CMV-CMI, the Quantiferon-CMV assay (Qiagen, Germantown, MD) was performed as per manufacturer's instructions. A detailed assay protocol has been described previously. Briefly, three 1-mL aliquots of whole blood were collected in a CMV tube, a nil tube (negative control), and a mitogen tube (positive control). The CMV tube is coated with a mix of 23 CMV CD8+ T cell synthetic epitopes (CMV tube) that include pp65, immediate early-1 (IE-1), IE-2, and gB. Tubes are incubated overnight at 37°C, followed by centrifugation and IFN-c measurement in the supernatant using an ELISA. All assays were performed in real time by a technician blinded to the clinical status of the patients. As per manufacturer's instructions, an IFN-c value of ≥0.2 IU/mL in the CMV tube (after subtraction of the nil tube) was considered a positive result. If the level was <0.2 IU/mL and the mitogen control was positive (≥0.5 IU/mL) the test was considered to be negative. If the mitogen tube was also negative, this result was considered indeterminate. For the purposes of the analysis, negative and indeterminate results were classified together as being negative (nonreactive).
CMV viral load assay: Viral load testing was performed on plasma samples using a commercially available PCR assay (Roche Ampliprep Assay; Roche Molecular Diagnostics, Pleasanton, CA) as per manufacturer's instructions. Assay results were reported in IU/mL as per the international World Health Organization standard. The assay has a LLoQ of 137 IU/mL.
The Monitor assay:
The QuantiFERON-Monitor assay (Qiagen) was used to measure cellular immune responses as per manufacturer's instructions. Briefly, 1 mL of whole blood was collected in a heparinized tube. A lyosphere containing anti-CD3 (T cell stimulant) and R848 (a NK cell stimulant) was added to the whole blood within 8 h of collection followed by incubation for 16-24 h at 37°C, after which it was centrifuged to obtain plasma. An ELISA for IFN-c was performed; values for IFN-c were obtained in IU/mL. For the purposes of the study, plasma was collected and stored at À80°C for batch testing. The assay results were not released to treating physicians and did not influence clinical decisions.
Statistical analysis
Descriptive statistics were used to analyze baseline characteristics of the cohort and to analyze CMV viral loads and IFN-c responses. The KaplanMeier method or the Mann-Whitney U test was used to determine differences in CMV recurrence among patient groups. All statistical analysis was performed using SPSS version 22.0 (IBM, Chicago, IL) and GraphPad Prism version 7 (La Jolla, CA).
Results
Patient characteristics
A total of 32 patients were enrolled in the study (Figure 1 ). Of these, 27 completed the study intervention and were available for further analysis. Baseline and demographic data on these 27 patients is shown in Table 1 . The most common transplant type was liver (37%) followed by kidney (25.9%) and lung (22.2%). The most common immunosuppression regimens consisted of a combination of tacrolimus and prednisone with or without mycophenolate. Median viral load at onset was 10 900 IU/mL and 15/27 (55.6%) had symptomatic CMV disease that included CMV viral syndrome (n = 12) and tissue invasive disease (n = 3). Prior to the episode of CMV reactivation, 20 patients had received previous prophylaxis and 7 were antiviral na€ ıve. All patients were treated with either intravenous ganciclovir or oral valganciclovir.
Clinical course
All patients responded to initial treatment with viral load reaching undetectable. Median time to undetectable viral load was 33 days (range 14-116). End-of-treatment was based on a single undetectable viral load in 12/27 (44.4%) or two viral loads <137 IU/mL in 15/27 (55.6%) patients. At the end of therapy, CD8+ CMV-specific CMI was measured in real time. These results are shown in Figure 2 . The mean IFN-c result was 2.96 AE 4.41 IU/mL and the median was 0.79 IU/mL (range 0-15.9; Figure 2 ). Using the predefined cut-off of 0.2 IU/mL (as per manufacturer's instructions), the CMI result was considered positive in 14/27 (51.9%) patients and negative in 13/27 (48.1%) patients. The result was used to guide antivirals as follows: antivirals were discontinued in all of the 14 patients who had a positive CMV-CMI result. In the remaining patients, valganciclovir was reduced to prophylaxis dose (900 mg/day) and continued for 2 months or as tolerated. No significant differences were noted in characteristics of CMI-positive versus CMI-negative patients (Table 2) .
Outcomes
Positive CMV-CMI patients: These patients (n = 14) did not receive secondary prophylaxis based on the result SOT paƟents screened for onset of viremia n=64
Enrolled n=32
EOT CMI collected n=27 (analysis populaƟon)
NegaƟve CMI (n=13) PosiƟve CMI (n=14) of the assay. The primary endpoint (clinically significant CMV recurrence) occurred only in a single patient in this group. This patient was a lung transplant recipient, CMV donor seropositive/recipient seronegative (D+/R-), who had received 12 months of antiviral prophylaxis. Initial CMV viremia occurred at 14 months posttransplant and was treated until undetectable viral load. Her mycophenolate dose was reduced from 720 mg bid to 360 mg bid. Thirtysix days after discontinuation of treatment, she had a viral load relapse of 2670 IU/mL. She was asymptomatic and was successfully treated with oral valganciclovir. No specific factors contributing to recurrence were noted.
Negative CMV-CMI patients: As noted above, these patients (n = 13) received antiviral prophylaxis. The rate of CMV recurrence was significantly higher in this group (9/13 [69.2%]; p = 0.001 compared with the CMV-CMI positive patients) ( Figure 3 ) and treatment dose antivirals were resumed in 8/9 (88.9%). The clinical course was as follows in these patients. Two patients had breakthrough viremia while on prophylaxis (viral load 916 IU/mL and 12800 IU/mL). One of these patients was successfully treated with full-dose valganciclovir while the second patient had a UL97 ganciclovir resistance mutation and eventually responded to foscarnet. Five patients had premature discontinuation of secondary prophylaxis due to neutropenia and shortly had recurrence after that (viral loads ranged from 538 to 73 600 IU/mL). In the remaining two patients, one developed viremia and was found to be noncompliant with valganciclovir and the other patient recurred after completing the 2 months of prophylaxis (viral loads 671 and 1630 IU/mL).
In the subgroup of patients with no clinically significant recurrence (13 patients in the positive CMI group and 4 patients in the negative CMI group), some had low-level viremia detected (<500 IU/mL; n = 6; 5/13 in the subgroup of positive CMI patients and 1/4 in the subgroup of negative CMI patients). None of these patients were treated and all resolved spontaneously after a single positive PCR.
Monitor assay
An exploratory substudy was performed to assess the functionality of a non-pathogen-specific assessment of immunity. The Monitor assay was performed on 24 patients at the end of treatment. Results were not used for clinical decision-making. The IFN-c result ranged from 0 to 527.5 IU/mL (median = 32.08; mean 87.0 AE 131.3). The Monitor result was compared between patients All patients received valganciclovir 900 mg daily for prophylaxis adjusted for renal function. who had clinically significant recurrence versus no recurrence; median IFN-c levels were 26.9 versus 46.4 IU/mL, respectively; p = 0.71, demonstrating that the non-pathogen-specific assessment of global immunity did not predict recurrence. Using the cohort median (32.08 IU/mL) to define a "positive" test, recurrence occurred in 4/12 (33.3%) patients above the median and 5/12 (41.7%) patients below the median value (p = 0.99).
Discussion
The enumeration and ex vivo assessment of the functionality of CMV-specific cell subsets is being increasingly advocated to categorize the actual risk of developing CMV disease in a given patient (7) . Such an approach should allow clinicians to at least in part individualize the prevention and treatment strategy against CMV. We report here the first study, to our knowledge, where a CMV-specific CMI assay was used in real time to make alterations to clinical care based on the result. Our study demonstrates that utilization of such an assay in real-time decision making is feasible in transplant patients and appears to be safe. Based on the assay results, a significant portion of patients had successful early discontinuation of antivirals after treatment completion. Despite early discontinuation, only one patient who had a positive assay had a clinically significant recurrence, which was still asymptomatic and a relatively low level of viremia. A somewhat unexpected finding was the high rate of recurrence observed in the group that had a negative CMV-CMI and received secondary antiviral prophylaxis. Much of this recurrence was in the setting of early discontinuation of prophylaxis due to leukopenia. This study therefore further highlights the limitations of secondary prophylaxis due to drug-related adverse events and possible lack of efficacy. Therefore, our results suggest that in patients with a positive CMI at the end of CMV treatment, it is probably a reasonable clinical strategy to discontinue antivirals at that point. However, those with a negative CMI likely require alternative strategies to prevent CMV recurrence. Although clinical factors may have been shown to predict CMV relapse such as type of transplant, D+/R-serostatus, and others, a simple standardized measurement tool or assay may be of greater clinical utility (1). We did not find any factors that identified patients more likely to have a negative CMI. However, we routinely do not perform quantitative immunoglobulin testing or posttransplant serology, which may be additional determinants.
CMV infection is known to result in robust immune responses from virtually every arm of the immune system (8) . However, the T cell-mediated adaptive immune response is predominant in the protection against CMV. Specifically, IFN-c producing CMV-specific CD8+ T cells appear to play a critical role in controlling CMV viremia.
Cytotoxic CD8+ T cells may target a great variety of viral proteins (approximately 70% of the viral proteome) and the responses against tegument phosphoprotein pp65 and IE-1 antigens are important (3, 9) . Several studies have been published over the last decade to evaluate the predictive value of cell-based immune assays for predicting events related to CMV reactivation (reviewed in reference 3) (3).
To assess a more generic global assessment of immunity that may be useful in this setting, we performed an exploratory substudy using the Monitor assay. The Monitor assay is based on stimulation of whole blood with a lyosphere containing anti-CD3 (T cell stimulant) and R848 (a Toll-like receptor stimulant). Since this assay nonspecifically stimulates elements of both the innate and adaptive immune system, it may be a reasonable measure of the overall degree of immunosuppression (10) . However, we demonstrate that IFN-c production using this assay was not different in the group with recurrence versus no recurrence. This suggests that CMV recurrence may be based more on pathogen-specific immune response rather than overall degree of immunosuppression in these patients.
Our study has several limitations. We acknowledge that the sample size is small; however, despite this small sample size, we believe we were able to convincingly demonstrate the feasibility of real-time use of CMV-CMI measurement in clinical decision making. We were also able to demonstrate a reasonable safety signal for early discontinuation of antivirals, although we acknowledge that a further demonstration in a larger cohort and preferably a randomized trial would be important. In addition, our study cohort primarily included those with asymptomatic viremia or mild-to-moderate CMV disease. Tissue-invasive disease was not well represented and the performance of CMI testing may differ in this circumstance. Finally, it was clear that many patients (5/13) were not able to tolerate secondary antiviral prophylaxis due to neutropenia and therefore our study highlights the limitations of current forms of secondary prophylaxis. Nevertheless, the purpose of our study was not to evaluate the utility of secondary prophylaxis, but rather to demonstrate feasibility and safety of real-time CMV-CMI assessment followed by early antiviral discontinuation in those who are positive. The assay used in our study measures primarily CD8+ T cell responses; however, other platforms such as flow cytometry or ELISPOT that assess both CD4+ and CD8+ T cell responses may provide a different assessment (3). Future studies could also measure CMI at the end of secondary prophylaxis. A negative CMI at this time may impact the decision to reduce immunosuppression or prolong antiviral prophylaxis.
In summary, these results provide a proof of principle that therapy for CMV can be safely personalized using measurements of CMV-specific CMI to allow early discontinuation of antivirals. Further interventional trials focusing on primary prevention may lead to additional refinement and personalization of strategies to mitigate CMV infection after transplantation.
